BUZZ-Pfizer rises on new COVID-19 vaccine booster data

Co says a late-stage study with 10,000 participants showed high efficacy of a booster dose of its COVID-19 vaccine against the virus

  

** Shares of Pfizer Inc rise ~1% to $43.2 premarket

** Co says a late-stage study with 10,000 participants showed high efficacy of a booster dose of its COVID-19 vaccine against the virus, including the Delta variant 

** The co and its German partner BioNTech also say research conducted in Israel shows that their COVID-19 vaccine is highly effective at preventing infection and symptomatic disease from the Delta variant among 12- to 18-year-olds.

** U.S. regulators have already authorized a third dose of PFE/BNTX's COVID-19 vaccine at least six months after the first round of shots, for people aged 65 and older and those at risk of severe disease

** Up to Wednesday's close, PFE up ~16.4% YTD

(Reporting by Manojna Maddipatla in Bengaluru) ((manojna.kalyani@thomsonreuters.com; +91 8061822700;))


More From Equities